http://www.bloomberg.com/apps/news?pid=20601101&sid=aSm.1Cdgn0_gThe company expects sales to begin in the year starting April 1, joining Shionogi & Co. in selling new flu drugs in the world’s second-biggest pharmaceutical market.
NTI Neurotech knocked back by FDA as agency declares target condition not rare enough for special status